Gravity Diagnostics: An In-Network Provider with All MCOs in Kentucky!

Gravity Diagnostics is proud to be an in-network provider with all Managed Care Organizations (MCOs) in the state of Kentucky, including WellCare, Anthem, Aetna, Humana, Molina, and UnitedHealthcare. This underscores our commitment to ensuring high-quality diagnostic services are accessible to everyone in our community.   Enhanced Access to Care   As an in-network provider, we…

Read More

2024 National Drug Threat Assessment and Gravity Diagnostics’ Trending Data

Authors:  Nicholas Lyktey, Chief of Laboratory Operations, and Jordan Kelsey, Clinical Product Specialist The Drug Enforcement Administration (DEA) released the 2024 National Drug Threat Assessment, which contains a comprehensive assessment of illicit drug threats and traffic trends in the United States. Gravity Diagnostics’ Team continues to be proactively educated on new drug trends and add…

Read More

Kentucky Biomarker Bill: The Right Test for the Right Treatment

Author: Dr. JP Canner, Ph.D., NRCC, MT(AAB) The right test for the right treatment.    The Commonwealth of Kentucky enacted HB180 this year which mandates insurance coverage of biomarker testing.  Kentucky joins 13 other states with legislation addressing this complex issue.   Biomarkers can either be direct targets or closely associated indicators of a disease. …

Read More

PGx: Truth, Hope, and Hype

Author: Dr. JP Canner, Ph.D., NRCC, MT(AAB) Pharmacogenetics (PGx) is the practice of applying the knowledge of an individual’s genes to guide the best therapeutic options.  Given the generality of this definition, there are numerous ways to implement PGx in practice.  In this article, we’ll cover the basics of PGx, detailing what it is and…

Read More

Xylazine: Still a Threat

Author: Dr. JP Canner, Ph.D., NRCC, MT(AAB)   Xylazine: Still a Threat In April 2023, Xylazine was designated as an emerging threat to the United States after a series of reports from the FDA (Food and Drug Administration) and DEA (Drug Enforcement Administration). (1) While the dangers of Xylazine have been documented, the prevalence of…

Read More

Gravity Diagnostics Expands Diagnostic Product Offerings by Launching Blood Testing

Gravity Diagnostics announces another expansion of their diagnostic product offerings with the addition of blood testing. Gravity currently serves over 1,000 customers nationwide, some of which include private practices, urgent cares, rehab and addiction clinics, pain management, and more. In July 2016, Gravity specialized primarily in toxicology testing, but quickly added pharmacogenomics, sexually transmitted infection testing,…

Read More

Have you ever heard of Pharmacogenomic (PGx) Testing?

Have you ever heard of Pharmacogenomic (PGx) Testing? A PGx test is used by a physician as a dosing guidance tool to help treat patients who are prescribed certain medications. Gravity Diagnostics offers PGx testing through a simple swab of the cheek—the following panels provide data for genes that code for over 130 medications: Mental…

Read More

The Importance of STI Tests

Have you ever been curious about the prevalence and importance of STIs? Gravity Diagnostics offers STI Testing through urine or e-genital swab for the following STIs: Herpes Simplex Virus 1 & 2 Chlamydia Trachomatis Gardnerella Vaginalis Ureaplasma Urealyticum Mycoplasma Genitalium Trichomonas Vaginalis Neisseria Gonorrhoeae Gravity’s STI requisition form indicates the best patient population to test,…

Read More

STI Testing

Did you know? Those who have Substance Use Disorders (SUDs) are at a higher risk for Sexually Transmitted Infections (STIs). Addiction recovery centers and substance abuse treatment centers present great opportunities to offer counseling for STIs. Those who have SUDs are at a higher risk for contracting an STI due to the behaviors associated with…

Read More